Africa: Momentum Builds For Long-Acting HIV Solutions As IAS 2025 Spotlights Scientific Progress, Funding Challenges And Leaders’ Calls To Action
New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly oral pill MK-8527 advances to Phase 3 trials in Africa 14 July 2025 (Kigali, Rwanda) – IAS 2025, the 13th IAS Conference on HIV Science, opened today with a call to accelerate…